This is Curacell
Curacell develops cell based immunotherapies for cancer treatment focusing on TILs (Tumor Infiltrating Lymphocytes), an investigational therapy aimed at a durable cure for solid tumor cancers.
The company is initiating its first clinical program targeting indications with high prevalence and the potential to make a significant impact on cancer patients worldwide.
TILs are a natural immune response to cancer. Curacell’s treatment is an autologous cell therapy built on a proprietary manufacturing process. It also involves a unique pre-regiment of patients and combination with other innovative cancer therapies.
Promising results from our scientific team members lay a strong foundation for Curacell’s next clinical stage.
Our team is growing at a high pace and we are always looking for new talent.
Do you want to make an impact for cancer patients? Are you ready for a new challenge? Please don't hesitate to reach out to us.